Skip to main content

Monoclonal Antibody Deal Benchmarks in Metabolic & Obesity

Median Upfront
$703M
Range: $386M - $1.0B
Total Deal Value
$3.3B
Range: $2.2B - $4.5B
Royalty Rate
14.7% - 26.9%
Tiered up to 30.9%
Dev Milestones
$474M
Range: $321M - $629M
Model Your Deal

Market Analysis

Monoclonal Antibody therapies in metabolic & obesity have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 monoclonal antibody asset in metabolic & obesity is $703M, with total deal values reaching $3.3B. Development milestones average $474M, while regulatory milestones contribute $579M.

The metabolic & obesity monoclonal antibody landscape is characterized by extremely high competitive intensity driven by the GLP-1 revolution and massive obesity market opportunity. Oral formulations, dual/triple incretins, and muscle-sparing approaches command unprecedented deal valuations. The recommended deal structure allocates approximately 21% to upfront payments and 79% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for monoclonal antibody metabolic & obesity deals range from 14.7% to 26.9% at the base tier, with tiered escalation reaching 18.7%-30.9% on blockbuster sales. Commercial milestones averaging $1.6B further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a monoclonal antibody metabolic & obesity licensing deal?
Based on our analysis, Phase 2 monoclonal antibody licensing deals in metabolic & obesity average $703M in upfront payments, with a range of $386M to $1.0B depending on data quality, competitive positioning, and territorial scope.
What is the total deal value for monoclonal antibody metabolic & obesity transactions?
The median total deal value for Phase 2 monoclonal antibody assets in metabolic & obesity is $3.3B, ranging from $2.2B to $4.5B. This includes development milestones ($474M), regulatory milestones ($579M), and commercial milestones ($1.6B).
What royalty rates are standard for monoclonal antibody deals in metabolic & obesity?
Base royalty rates for monoclonal antibody metabolic & obesity transactions range from 14.7% to 26.9%, with tiered escalations reaching 18.7%-30.9% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.
How are milestones structured in monoclonal antibody metabolic & obesity deals?
Monoclonal Antibody metabolic & obesity deals allocate approximately 79% of total deal value to milestones. Development milestones ($474M) make up the largest share, followed by commercial milestones ($1.6B) and regulatory milestones ($579M).
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Small Molecule in Metabolic & Obesity

View

GLP-1 Agonist in Metabolic & Obesity

View

Monoclonal Antibody in Oncology

View

Monoclonal Antibody in Neurology

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included